|
|
|
|
|
|
Sponsored by: |
Gloucester Pharmaceuticals |
Information provided by: | Gloucester Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00106418 |
The purpose of this study is to evaluate the activity of romidepsin (depsipeptide,FK228) in patients with metastatic prostate cancer who have developed a rising prostate specific antigen (PSA) while undergoing hormonal therapy.
Condition | Intervention | Phase |
Prostate Cancer Metastases |
Drug: romidepsin (depsipeptide, FK228) |
Phase II |
MedlinePlus related topics: | Cancer Prostate Cancer |
ChemIDplus related topics: | FR 901228 |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Exploratory Phase II, Multicenter, Open-Label Trial Evaluating the Activity and Tolerability of FK228 in Androgen Independent Metastatic Prostate Cancer Patients With Rising PSA |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Inadequate bone marrow or other organ function, as evidenced by:
Study ID Numbers: | FJ-228-0002 |
First Received: | March 24, 2005 |
Last Updated: | December 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00106418 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|